“suisonia”, a medical inhaler developed and manufactured by Suisonia Co Ltd, have undergone a clinical trial for patients with Asthma and COPD. This research was conducted at Peking Union Hospital, and published at Oxford University Press. The research journal is entitled, “Hydrogen gas (XEN) inhalation ameliorates airway inflammation in asthma and COPD patients”
What the research was all about?
This research focuses to investigate the acute effects of inhaled hydrogen on airway inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD).
In this research, twenty (20) subjects were tested while each of them inhaled suisonia steam for 45 minutes. Suisonia inhaler was used in this research.
45 minutes of suisonia inhalation showed positive effects.
In conclusion to this research, a single inhalation of hydrogen for 45 minutes have shown effects that anticipates the use of suisonia in future medicines.
Inflammatory biomarkers such as monocyte chemotactic protein (MCP1), Interleukin 8, interleukin, soluble cluster of differentiation-40 ligand from exhaled breath condensate (EBC),
Study suggests, inhalation of suisonia steam once for 45 minutes showed positive therapeutic effect on airway inflammation in patients with asthma and COPD.
Research Published to Oxford University Press
This clinical trial research was published on Oxford University Press (QJM: An International Journal of Medicine, hcaa164) May 14th, 2021.
S -T Wang, C Bao, Y He, X Tian, Y Yang, T Zhang, K -F Xu, Hydrogen gas (XEN) inhalation ameliorates airway inflammation in asthma and COPD patients, QJM: An International Journal of Medicine, Volume 113, Issue 12, December 2020, Pages 870–875, https://doi.org/10.1093/qjmed/hcaa164